Fig. 2

Efficacy, adverse events, and survival outcome of bispecific antibody treatment and ICI combination therapies in patients with hematological malignancies. a A histogram depicting the antitumor efficacy of BSABs and ICIs combination therapies as applied to patients with B-cell lymphoma/leukemia. The ORR, defined as a sum of CR and PR. ORR, overall response rate; CR, complete remission; PR, partial response; Ipi, Ipilimumab (anti-CTLA-4); Nivo, Nivolumab (anti-PD-1); BV, Brentuximab vedotin. b A forest plot charting the survival outcomes (unit is month) of BSABs and ICIs combination therapies in patients with B-cell lymphoma/leukemia. OS, overall survival; PFS, progression-free survival; DoR, duration of response; NR, not reached. c A histogram depicting the incidence of grade ≥ 3 adverse events (AEs), as well as the major compositions of grade ≥ 3 AEs or treatment-related adverse events (TRAEs) with BSABs and ICIs combination therapies in patients with B-cell lymphoma/leukemia. A bar with a value of 0 means not mentioned in the article. d A histogram depicting the antitumor efficacy of BSABs and ICIs combination therapies as applied to patients with multiple myeloma. e A forest plot charting the survival outcomes of BSABs and ICIs combination therapies in patients with multiple myeloma. f A histogram depicting the incidence of the composition of major grade ≥ 3 AEs for the treatment of BSABs and ICIs combination therapies for multiple myeloma, with cytokine release syndrome (CRS, all-grade), while other adverse events were graded as tertiary or higher